Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AAPG
Upturn stock ratingUpturn stock rating

Ascentage Pharma Group International (AAPG)

Upturn stock ratingUpturn stock rating
$39.6
Last Close (24-hour delay)
Today's Top PicksToday’s top pick
Profit since last BUY50.57%
upturn advisory
Strong Buy
BUY since 44 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: AAPG (3-star) is a STRONG-BUY. BUY since 44 days. Profits (50.57%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

2 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $

Year Target Price $

Analyst’s Price TargetsFor last 52 week
$Target price
Low$16.5
Current$39.6
high$40.81

Analysis of Past Performance

Type Stock
Historic Profit 50.57%
Avg. Invested days 44
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 6.35B USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 1
52 Weeks Range 16.50 - 40.81
Updated Date 05/15/2025
52 Weeks Range 16.50 - 40.81
Updated Date 05/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.17

Earnings Date

Report Date 2025-07-03
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -39.9%
Operating Margin (TTM) 22.82%

Management Effectiveness

Return on Assets (TTM) -7.14%
Return on Equity (TTM) -52.38%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1665238458
Price to Sales(TTM) 7.03
Enterprise Value 1665238458
Price to Sales(TTM) 7.03
Enterprise Value to Revenue 13.44
Enterprise Value to EBITDA -
Shares Outstanding 348267008
Shares Floating 174845965
Shares Outstanding 348267008
Shares Floating 174845965
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating 4.5
Target Price -
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Ascentage Pharma Group International

stock logo

Company Overview

overview logo History and Background

Ascentage Pharma Group International is a global biopharmaceutical company focused on developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. While founded in China in 2009, it has a US presence. Milestones include the development of core drug candidates and strategic collaborations.

business area logo Core Business Areas

  • Oncology Drug Development: Focuses on developing and commercializing innovative therapies for hematologic malignancies and solid tumors.
  • Chronic Hepatitis B (CHB): Develops therapies to address unmet needs in chronic hepatitis B treatment.
  • Age-Related Diseases: Research and development of novel therapies targeting age-related diseases.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure is typically hierarchical, with departments focused on R&D, clinical development, manufacturing, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Olverembatinib (HQP1351): A third-generation BCR-ABL inhibitor approved in China for treatment-resistant chronic myeloid leukemia (CML). Market share data specific to the US market is not readily available, as the drug is not yet FDA-approved. Competitors include Novartis' Tasigna and Sprycel, Bristol Myers Squibb's Sprycel.
  • APG-115 (Lisaftoclax): A Bcl-2 inhibitor in clinical development for various hematological malignancies. No revenue data is publicly available. Competitors include AbbVie's Venclexta.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The oncology market is rapidly growing, driven by increasing cancer incidence and advances in treatment options.

Positioning

Ascentage Pharma is positioning itself as an innovative biopharmaceutical company with a focus on developing novel targeted therapies for cancer and other diseases. Its competitive advantage lies in its proprietary drug discovery platform and clinical development expertise.

Total Addressable Market (TAM)

The global oncology drug market is estimated to be worth hundreds of billions of dollars. Ascentage Pharma aims to capture a significant portion of this market with its innovative therapies, focusing on targeted therapies with potential for higher efficacy and fewer side effects.

Upturn SWOT Analysis

Strengths

  • Innovative drug discovery platform
  • Strong pipeline of novel drug candidates
  • Experienced management team
  • Strategic partnerships with leading pharmaceutical companies

Weaknesses

  • Limited commercial infrastructure in the US market
  • Reliance on external funding for R&D
  • High R&D costs and long development timelines
  • Dependence on key drug candidates for future growth

Opportunities

  • Expansion into new therapeutic areas
  • FDA Approval of drugs in clinical trials
  • Strategic acquisitions of complementary technologies or companies
  • Partnerships with larger pharmaceutical companies for commercialization

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles and delays in drug approval
  • Patent expiration and generic competition
  • Economic downturns and changes in healthcare policy

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • BMY
  • ABBV

Competitive Landscape

Ascentage Pharma faces intense competition from established pharmaceutical companies with larger resources and broader product portfolios. Its advantages include its innovative drug discovery platform and focus on developing targeted therapies for unmet medical needs. Its disadvantages include its smaller size and limited commercial infrastructure.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by progress in clinical trials, regulatory approvals in China, and expansion of the pipeline.

Future Projections: Future growth is dependent on the success of ongoing clinical trials, regulatory approvals in key markets (including the US), and commercialization of new products. Analyst estimates are not available.

Recent Initiatives: Recent initiatives include advancing clinical trials for key drug candidates, seeking regulatory approvals in new markets, and expanding partnerships with other pharmaceutical companies.

Summary

Ascentage Pharma is an innovative biopharmaceutical company with a promising pipeline, but it faces significant challenges in a competitive industry. Its strength lies in its novel drug discovery platform and its established presence in China. The company needs to secure US FDA approvals. It also needs to carefully manage its cash flow and address competition from larger pharmaceutical companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings of Competitors
  • Industry Reports

Disclaimers:

This analysis is based on publicly available information and general industry knowledge. It should not be considered financial advice. Market share data is estimated and may not be precise. Financial metrics are difficult to interpret due to primary listing outside the US.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ascentage Pharma Group International

Exchange NASDAQ
Headquaters -
IPO Launch date 2025-01-24
Co-Founder, Chairman & CEO Dr. Dajun Yang M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 567
Full time employees 567

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.